These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38876129)

  • 41. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
    Tani C; Elefante E; Signorini V; Zucchi D; Lorenzoni V; Carli L; Stagnaro C; Ferro F; Mosca M
    RMD Open; 2019; 5(2):e000916. PubMed ID: 31275608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients.
    Zen M; Iaccarino L; Gatto M; Bettio S; Saccon F; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2017 Mar; 76(3):562-565. PubMed ID: 27884821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
    Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
    Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus.
    Elefante E; Tani C; Stagnaro C; Signorini V; Parma A; Carli L; Zucchi D; Ferro F; Mosca M
    Arthritis Res Ther; 2020 Oct; 22(1):241. PubMed ID: 33054823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
    Altabás-González I; Rúa-Figueroa I; Rubiño F; Mouriño Rodríguez C; Hernández-Rodríguez I; Menor Almagro R; Uriarte Isacelaya E; Tomero Muriel E; Salman-Monte TC; Carrión-Barberà I; Galindo M; Rodríguez Almaraz EM; Jiménez N; Inês L; Pego-Reigosa JM
    Rheumatology (Oxford); 2023 Mar; 62(3):1162-1169. PubMed ID: 35961050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).
    Babaoglu H; Li J; Goldman D; Magder LS; Petri M
    Lupus; 2019 Dec; 28(14):1648-1655. PubMed ID: 31694446
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of the Asia Pacific Lupus Collaboration cohort.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Luo SF; Jan Wu YJ; Li Z; An Y; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Hao Y; Zhang Z; Al-Saleh J; Khamashta M; Takeuchi T; Tanaka Y; Bae SC; Lau CS; Hoi A; Nikpour M; Morand EF
    Int J Rheum Dis; 2019 Mar; 22(3):425-433. PubMed ID: 30398013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predicting lupus low disease activity state and remission in SLE: novel insights.
    Gao D; Hao Y; Fan Y; Ji L; Zhang Z
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1083-1089. PubMed ID: 34392757
    [No Abstract]   [Full Text] [Related]  

  • 51. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
    Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
    Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
    Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low disease activity state in juvenile-onset systemic lupus erythematosus.
    Ozturk K; Caglayan S; Tanatar A; Baglan E; Yener Otar G; Kavrul Kayaalp G; Karadag SG; Demir F; Sonmez HE; Ozdel S; Cakan M; Aktay Ayaz N; Sozeri B;
    Lupus; 2021 Nov; 30(13):2144-2150. PubMed ID: 34723709
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus.
    Kandane-Rathnayake R; Kent JR; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra SA; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Hoi A; Nikpour M; Morand E
    Lupus; 2019 Dec; 28(14):1669-1677. PubMed ID: 31718467
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Burden of lupus activity on health care resources utilization in Buenos Aires, Argentina.
    Alvarado RN; Alle G; Tobar-Jaramillo MA; Palomino LC; Cáceres AG; Rosa JE; Machnicki G; Zazzetti F; Soriano E; Scolnik M
    Lupus; 2023 Dec; 32(14):1656-1665. PubMed ID: 37955177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study.
    Connelly K; Kandane-Rathnayake R; Hoi A; Louthrenoo W; Hamijoyo L; Luo SF; Wu YJ; Cho J; Lateef A; Lau CS; Chen YH; Navarra S; Zamora L; Li Z; An Y; Sockalingam S; Hao Y; Zhang Z; Chan M; Katsumata Y; Harigai M; Oon S; Bae SC; O'Neill S; Gibson KA; Basnayake B; Kikuchi J; Takeuchi T; Ng KPL; Tugnet N; Kumar S; Goldblatt F; Law A; Tee M; Tee C; Tanaka Y; Ohkubo N; Tan JY; Karyekar CS; Nikpour M; Golder V; Morand EF
    Arthritis Rheumatol; 2023 Mar; 75(3):401-410. PubMed ID: 36122172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study.
    Louthrenoo W; Kasitanon N; Morand E; Kandane-Rathnayake R
    Arthritis Res Ther; 2020 Jan; 22(1):8. PubMed ID: 31924267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.